Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci120 in Rheumatoid Arthritis
NCT07423533Phase 2Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of GenSci120 in rheumatoid arthritis (RA), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Apr 2026; status: recruiting.
02
Drugs
GenSci120
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07423533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423533.